Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07162467

Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.

Sponsor: Tianjin Anding Hospital

View on ClinicalTrials.gov

Summary

Schizophrenia is a common, long-term mental illness. It causes problems with thoughts, feelings, and behavior, including positive symptoms (hallucinations, delusions), negative symptoms (lack of emotion, motivation), and cognitive impairment (trouble with thinking, memory, and attention). While antipsychotic drugs effectively treat positive symptoms, they don't help much with cognitive impairment.This study will examine how the tryptophan-kynurenine pathway in the brain contributes to cognitive problems in people having their first episode of schizophrenia and treated with a single antipsychotic. Our goal is to create models for early detection of cognitive impairment in schizophrenia and find potential targets for new treatments to improve thinking and memory.

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

OBSERVATIONAL

Enrollment

200

Start Date

2024-02-19

Completion Date

2026-06-30

Last Updated

2026-01-14

Healthy Volunteers

Yes

Conditions

Locations (1)

Tianjin Anding Hospital

Tianjin, China